Zinger Key Points
- Inspira’s VORTX tech oxygenates blood without harmful fiber membranes, reducing turbulence and clotting risks.
- VORTX is designed to assist 20 million ICU respiratory failure patients annually, offering safer blood flow support.
- Get 5 New Stock Recommendations Every Week
On Tuesday, Inspira Technologies OXY B.H.N. Ltd. IINN announced the development of a modular configuration for its VORTX blood oxygenation delivery technology.
As per the company website, the VORTX technology is designed to enrich small volumes of blood with oxygen and simultaneously remove carbon dioxide to elevate saturation levels to 95% or higher.
The VORTX aims to oxygenate blood without fiber membranes, which are known to cause harmful turbulence, friction, and shear forces, increasing damage to blood cells and clotting.
The modular configuration of the VORTX blood oxygenation delivery system is expected to extend the INSPIRA Augmented Respiration Technology’s (ART) range of blood oxygen enrichment and carbon dioxide removal.
The flagship INSPIRA ART system aims to revolutionize the $19 Billion Mechanical ventilation market and is being designed to elevate and stabilize declining oxygen saturation levels in patients while they are awake and without a ventilator.
The company adds that, unlike traditional fiber-based oxygenators, the VORTX is designed to maintain a more natural blood flow, potentially reducing harmful effects on blood components. Thirty-two novel patent claims protect the technology.
In September, Inspira secured an additional U.S. Patent approval for the VORTX orbiting blood oxygenation delivery system.
The technology can provide life-saving support for the approximately 20 million ICU patients with respiratory failure annually.
Recently, Inspira announced that it is preparing for a potential production ramp-up of its INSPIRA ART100 device in light of the recent human metapneumovirus (hMPV) outbreak in China.
Price Action: IINN stock is down 1.89% at $1.04 during the premarket session at last check Tuesday.
Read Next:
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
